Bioequivalence testing emerging as critical issue in domestic pharmaceutical industry

Published: 2003-02-13 06:58:00

Updated: 2003-02-13 06:58:00

Pharmaceutical business sources say that pharmaceutical manufacturing firms should pay more attention to bioequivalence testing due to that a variety of government policies designed to stabilize the finance of National Health Insurance Corporation have been implemented via activation of substitut...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK